What Royalty Pharma PLC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 7 | 74 |
| Total trades | 13 | 105 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 105 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | Oct 05 | Open-market sale · S | −4,126 | $57.10 | −$236K | 0 |
| Bassler Bonnie L | Director | Sep 30 | Grant / award · A | +642 | $58.41 | +$37.5K | 79,823 |
| Urist Marshall | EVP, Research & Investments | Sep 28 | Open-market sale · S | −4,126 | $57.88 | −$239K | 4,126 |
| Hite Christopher | EVP & Chairman, Partnering | Sep 22 | Open-market sale · S | −3,927 | $58.93 | −$231K | 270,401 |
| Hite Christopher | EVP & Chairman, Partnering | Sep 22 | Open-market sale · S | −96,073 | $58.51 | −$5.62M | 274,328 |
| Hite Christopher | EVP & Chairman, Partnering | Aug 19 | Gift · G | −16,800 | — | — | 23,200 |
| Hite Christopher | EVP & Chairman, Partnering | Aug 18 | Open-market sale · S | −100,000 | $59.97 | −$6M | 370,401 |
| Coyne Terrance P. | EVP & CFO | Aug 13 | Open-market sale · S | −1,772 | $59.14 | −$105K | 0 |
| Coyne Terrance P. | EVP & CFO | Aug 13 | Open-market sale · S | −9,230 | $58.59 | −$541K | 1,772 |
| Legorreta Pablo G. | CEO, Chairman of the Board | Aug 05 | Grant / award · A | +65,216 | — | — | 1,307,820 |
| Hite Christopher | EVP & Chairman, Partnering | Aug 05 | Grant / award · A | +11,002 | — | — | 470,401 |
| Coyne Terrance P. | EVP & CFO | Aug 05 | Grant / award · A | +11,002 | — | — | 11,002 |
| Urist Marshall | EVP, Research & Investments | Aug 05 | Grant / award · A | +8,252 | — | — | 8,252 |
| Urist Marshall | EVP, Research & Investments | Jul 01 | Open-market sale · S | −9,099 | $55.88 | −$508K | 0 |
| Bassler Bonnie L | Director | Jun 30 | Grant / award · A | +689 | $54.40 | +$37.5K | 79,181 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 30 | Open-market sale · S | −600 | $57.09 | −$34.3K | 40,000 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 30 | Open-market sale · S | −29,400 | $56.44 | −$1.66M | 40,600 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 30 | Open-market sale · S | −2,554 | $57.10 | −$146K | 459,399 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 30 | Open-market sale · S | −97,446 | $56.50 | −$5.51M | 461,953 |
| Urist Marshall | EVP, Research & Investments | Jun 24 | Open-market sale · S | −9,098 | $55.18 | −$502K | 9,099 |
Loading...
